- Home
- ICCM vs TXMD Comparison
ICCM vs TXMD Comparison
Compare ICCM & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ICCM | TXMD |
|---|---|---|
| Founded | 2006 | 2008 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.4M | 24.4M |
| IPO Year | 2013 | 2012 |
Fundamental Metrics
Financial Performance| Metric | ICCM | TXMD |
|---|---|---|
| Price | $3.38 | $2.06 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $2.50 | N/A |
| AVG Volume (30 Days) | ★ 8.8M | 29.0K |
| Earning Date | 05-27-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 73.68 |
| EPS | N/A | ★ 0.01 |
| Revenue | N/A | ★ $1,761,000.00 |
| Revenue This Year | $139.51 | N/A |
| Revenue Next Year | $75.66 | N/A |
| P/E Ratio | ★ N/A | $211.00 |
| Revenue Growth | N/A | ★ 35.25 |
| 52 Week Low | $0.13 | $0.99 |
| 52 Week High | $9.54 | $2.95 |
Technical Indicators
Market Signals| Indicator | ICCM | TXMD |
|---|---|---|
| Relative Strength Index (RSI) | 45.58 | 51.65 |
| Support Level | $0.48 | $1.90 |
| Resistance Level | $5.69 | $2.23 |
| Average True Range (ATR) | 0.34 | 0.11 |
| MACD | -0.28 | 0.01 |
| Stochastic Oscillator | 4.48 | 37.80 |
Price Performance
Historical ComparisonAbout ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company that owns and manages intellectual property, including trademarks and product rights, which are licensed to third-party pharmaceutical companies. The company generates revenue mainly through royalties and milestone payments from licensed products, including IMVEXXY, BIJUVA, and ANNOVERA, and does not directly manufacture or market pharmaceutical products.